Heparin Sodium Panpharma

Heparin Sodium Panpharma is a pharmaceutical product containing the active ingredient heparin sodium, supplied in an injectable form for intravenous or subcutaneous administration. It is manufactured by Panpharma and marketed within the European Union. As an anticoagulant, it works by enhancing antithrombin III activity, which reduces clot formation. The product is available only by prescription and is used under medical supervision and requires careful monitoring by healthcare professionals.

Heparin Sodium Panpharma is indicated for several antithrombotic indications in clinical practice.

- Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism, especially in hospitalized or postoperative patients. - Management of acute coronary syndrome such as unstable angina and myocardial infarction, often in combination with antiplatelet agents. - Use as a heparin lock solution to maintain catheter patency and prevent line occlusion in intravenous therapy. - Peri‑operative anticoagulation for patients undergoing surgery who are at increased risk of thrombosis. - Adjunct therapy during extracorporeal circulation procedures, including cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO). - Prophylaxis of clot formation during hemodialysis or continuous renal replacement therapy.

Heparin Sodium Panpharma can cause adverse effects that are grouped by frequency and clinical importance.

Common: - Minor bleeding at the injection site or bruising, usually self‑limited and not requiring medical intervention. - Small drops in platelet count (thrombocytopenia) without clinical sequelae, often detected only on routine laboratory monitoring. - Elevated liver enzymes observed in laboratory tests, typically transient and returning to baseline after therapy cessation. - Transient rise in serum potassium levels, generally mild and asymptomatic.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding, which can be life‑threatening and may require urgent reversal of anticoagulation. - Heparin‑induced thrombocytopenia (HIT) with a paradoxical risk of thrombosis, necessitating immediate discontinuation and alternative anticoagulant therapy. - Spinal or epidural hematoma after neuraxial procedures, potentially causing neurologic deficits if not promptly recognized. - Allergic reactions such as urticaria, angioedema, or anaphylaxis, requiring emergency treatment and discontinuation of the product.

When prescribing or administering Heparin Sodium Panpharma, clinicians should observe several precautionary measures to minimize risk.

- Assess patient history for bleeding disorders, recent surgery, or trauma before initiating therapy. - Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels regularly to maintain therapeutic range. - Evaluate platelet counts frequently to detect heparin‑induced thrombocytopenia early. - Use caution in patients with renal or hepatic impairment, adjusting dose as needed. - Avoid concurrent use of other anticoagulants or antiplatelet agents unless clinically justified. - Educate patients on signs of bleeding and instruct them to report any unusual bruising or hemorrhage promptly.

Heparin Sodium Panpharma may interact with other medicines, influencing anticoagulant effect or bleeding risk.

Avoid: - Concurrent use of other systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) unless closely monitored. - Simultaneous administration of thrombolytic agents (e.g., alteplase) due to heightened hemorrhagic potential. - Use of high‑dose heparin in patients receiving fibrinolytic therapy should be avoided due to additive anticoagulant effect.

Use with caution: - Combination with antiplatelet drugs such as aspirin or clopidogrel, requiring careful assessment of bleeding risk. - Concomitant use of non‑steroidal anti‑inflammatory drugs (NSAIDs) or corticosteroids, which may exacerbate gastrointestinal bleeding. - Co‑administration with drugs that affect platelet function (e.g., selective serotonin reuptake inhibitors) should be evaluated.